Literature DB >> 1463794

Liquid chromatographic determination of a new catechol-O-methyltransferase inhibitor, entacapone, and its Z-isomer in human plasma and urine.

M Karlsson1, T Wikberg.   

Abstract

Assay procedures for analysis of entacapone, (E)-2-cyano-N,N-diethyl-3-(3,4-dihydroxy-5-nitrophenyl)-propenamide++ +, and its Z-isomer in human plasma and urine are described. The methods were based on reversed-phase liquid chromatography with amperometric detection. Entacapone and its Z-isomer were extracted with n-hexane-ethyl acetate mixtures after acidification with hydrochloric acid. From urine extracts the analytes were back-extracted into phosphate buffer (pH 7.2). During sample treatment 1-2% of entacapone was changed to the Z-isomer. With recoveries exceeding 75% the relative standard deviations for within-day precision were less than 11% for plasma and less than 6% for urine at the quantitation limit (10 ng ml-1) and less than 6% for both methods at higher concentrations (20-2000 ng ml-1). The assays were specific with respect to all known metabolites and selective, sensitive and precise enough for determination of entacapone and its Z-isomer in plasma and urine down to 10 ng ml-1. The methods are thus suitable for the kind of pharmacokinetic studies exemplified in this paper.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1463794     DOI: 10.1016/0731-7085(92)80085-2

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  8 in total

1.  A Novel Approach using Hydrotropic Solubalization Technique for Quantitative Estimation of Entacapone in Bulk Drug and Dosage Form.

Authors:  Ruchi Jain; Nilesh Jain; Deepak Kumar Jain; Surendra Kumar Jain
Journal:  Adv Pharm Bull       Date:  2013-08-20

2.  The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease.

Authors:  P Piccini; D J Brooks; K Korpela; N Pavese; M Karlsson; A Gordin
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-05       Impact factor: 10.154

Review 3.  Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease.

Authors:  Dirk Deleu; Margaret G Northway; Yolande Hanssens
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

4.  Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone.

Authors:  T Keränen; A Gordin; M Karlsson; K Korpela; P J Pentikäinen; H Rita; E Schultz; L Seppälä; T Wikberg
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

5.  Entacapone improves the availability of L-dopa in plasma by decreasing its peripheral metabolism independent of L-dopa/carbidopa dose.

Authors:  Helena Heikkinen; Anu Varhe; Tarmo Laine; Jaakko Puttonen; Marjo Kela; Seppo Kaakkola; Kari Reinikainen
Journal:  Br J Clin Pharmacol       Date:  2002-10       Impact factor: 4.335

6.  Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease.

Authors:  V V Myllylä; K A Sotaniemi; A Illi; K Suominen; T Keränen
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

7.  The effects of the COMT inhibitor entacapone on haemodynamics and peripheral catecholamine metabolism during exercise.

Authors:  S Sundberg; M Scheinin; A Illi; J Akkila; A Gordin; T Keränen
Journal:  Br J Clin Pharmacol       Date:  1993-11       Impact factor: 4.335

8.  Entacapone Treatment Modulates Hippocampal Proteins Related to Synaptic Vehicle Trafficking.

Authors:  Dae Young Yoo; Hyo Young Jung; Woosuk Kim; Kyu Ri Hahn; Hyun Jung Kwon; Sung Min Nam; Jin Young Chung; Yeo Sung Yoon; Dae Won Kim; In Koo Hwang
Journal:  Cells       Date:  2020-12-18       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.